Bruker (NASDAQ:BRKR) Earns “Buy” Rating from Guggenheim

Guggenheim reissued their buy rating on shares of Bruker (NASDAQ:BRKR) in a research note released on Monday,Benzinga reports.

Several other equities analysts have also recently issued reports on BRKR. The Goldman Sachs Group upgraded Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price target on the stock in a research report on Thursday, December 5th. TD Cowen decreased their target price on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a report on Wednesday, November 6th. Wells Fargo & Company decreased their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Bank of America lifted their target price on Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Finally, UBS Group assumed coverage on Bruker in a report on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 target price on the stock. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Bruker has a consensus rating of “Moderate Buy” and a consensus price target of $70.50.

Bruker Stock Down 1.0 %

Shares of BRKR stock opened at $50.49 on Monday. Bruker has a 1 year low of $48.07 and a 1 year high of $94.86. The stock has a market cap of $7.65 billion, a PE ratio of 66.43, a price-to-earnings-growth ratio of 2.16 and a beta of 1.16. The business’s fifty day moving average is $56.39 and its 200-day moving average is $59.81. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Equities analysts expect that Bruker will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a yield of 0.40%. Bruker’s payout ratio is 26.32%.

Institutional Trading of Bruker

A number of institutional investors have recently bought and sold shares of the company. True Wealth Design LLC raised its holdings in Bruker by 4,636.4% during the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock valued at $36,000 after buying an additional 510 shares in the last quarter. Eagle Bay Advisors LLC raised its holdings in Bruker by 2,324.1% in the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 674 shares in the last quarter. UMB Bank n.a. grew its stake in shares of Bruker by 37.5% in the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 248 shares during the period. GAMMA Investing LLC grew its stake in shares of Bruker by 47.5% in the 4th quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company’s stock valued at $75,000 after purchasing an additional 412 shares during the period. Finally, Quadrant Capital Group LLC grew its stake in shares of Bruker by 18.2% in the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company’s stock valued at $75,000 after purchasing an additional 196 shares during the period. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.